FYI *In the last 12 months Culper have put out just 6 research reports. *This Acadia report is 16 pages long [very detailed with numerous links] and could not have been put together at short notice. *The Gene Therapy [and other proposed alternative treatments for Retts] as a reason for patients to discontinue Daybue seems a bit of a stretch at this time. *This document certainly looks to me like a document prepared for something way in excess for a reason to short Acadia.It could have been put together for example for a third party with the intent to damage both Neuren and Acadia for their own objectives. *In my view this report certainly has not surfaced at this time because of a possible margin call on Culper now.
Just my musings
Kens
NEU Price at posting:
$19.78 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)